Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanthanum Carbonate in CAPD Patients with Hyperphosphatemia
NCT01518387Phase 3Completed
- Sponsor
- Bayer
- Start
- Jan 2006
- Primary completion
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lanthanum carbonate in hyperphosphatemia, sponsored by Bayer. Primary endpoint: Change from baseline in serum phosphate levels at 8 weeks. Started Jan 2006; status: completed.
02
Drugs
lanthanum carbonate
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT01518387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01518387.